Catheter-mediated, percutaneous, transluminal delivery of naked plasmid DNA (pDNA) into myocardium may offer a valuable strategy to heart diseases. Here, we examined whether clinically available transthoracic direct current (DC) shock improves intracoronary naked DNA transfection into myocardium. Plasmid vector encoding the GL3 luciferase was infused retrogradely into the coronary veins of beagle dogs, whereas another pDNA solution was infused into the left coronary artery. During and after these procedures, the coronary venous sinus was occluded by balloon, and transthoracic DC shock of 200 J was applied immediately after the infusions. Without DC shock, no remarkable increase in luciferase activity was demonstrated in any part of the left ventricular myocardium. In the presence of DC pulsation, significant luciferase expression was detected in the regions that were supplied by left anterior descending coronary artery (LAD), whereas the gene expression in the right coronary artery (RCA) regions was much less drastic. X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside) staining of cardiac cross-sections also revealed regional expression of b-galactosidase. Immunohistochemical examinations of heart cryosections revealed that cardiomyocytes in LAD regions successfully expressed transgene product. The present system may enable a new strategy for myocardial gene therapy, without any special device or technique other than cardiac catheterization and DC cardioversion that are generally performed in ordinary hospitals. Gene Therapy (2006) 13, 906-916.
Introduction
As a research tool to investigate the pathophysiological and molecular mechanisms of cardiovascular disorders, and as an essential means of gene therapy for heart diseases, a gene transfer technique that is highly efficient, repeatable and widely applicable without myocardial toxicity is desired. Currently, in vivo gene transfer into myocardium is performed by direct intracardiomuscular injection [1] [2] [3] [4] [5] [6] [7] [8] or transcoronary infusion 4,9-12 of viral vectors [1] [2] [3] [4] [9] [10] [11] [12] or nonviral vectors. [5] [6] [7] [8] The usefulness of viral vectors, including retrovirus vectors, adenovirus vectors and adeno-associated virus (AAV) vectors, has been accepted owing to their high transduction efficiency. However, viral vector-based transduction may cause severe side effects, for example, possible insertional mutagenesis induced by retrovirus vectors and inflammatory responses induced by adenovirus vectors. Recent improvements in AAV vectors enabled efficient intracardiac genetic transduction without significant toxicity, [13] [14] [15] but AAV vectors accommodate only relatively small DNA inserts, and infection in vivo with an AAV vector may induce antibody, which limits the effectiveness of repetitive administrations.
In contrast, naked DNA methods are advantageous over viral vectors, in terms of low toxicity, low immunogenicity and absence of restriction on the insert size. Another important advantage of naked DNA is their large-scale, affordable manufacture. However, critical shortage of nonviral gene delivery systems is that the transfection efficiency and the expression level are relatively insufficient. 16, 17 To overcome these problems, physical methods, including the gene gun procedure, 18 have been investigated. Ultrasonic wavemediated transduction of the plasmid DNA (pDNA)-microbubble conjugates has also been devised. [19] [20] [21] These physical nonviral procedures, as well as synthetic nonviral vectors such as cationic lipids [22] [23] [24] and cationic polymers, 25, 26 remain impractical for treating patients with heart diseases, mainly because of their lack of effectiveness.
Another promising method to increase naked DNA transduction efficiency is electroporation. In this method, application of an electric field forms pores in the lipid membrane, allowing influx of extracellular substances such as nucleic acids into the cell. 27 Electroporation has the following advantages: (1) genes may be introduced into any tissues or cells, (2) the procedure is easy and very rapid, requiring application of the electric field for only a few seconds, (3) the amount or size of DNA used is not stringently restricted, compared with the limitation in other gene delivery procedures, (4) introduction of genes can be limited to the region charged with an electric field, (5) repeated DNA administration is possible because of low immunogenicity and (6) the procedure requires no special skill and is inexpensive. Therefore, electroporation has been applied to not only cultured cells in vitro but also to organs/tissues in vivo, 28, 29 including skeletal muscle, 30, 31 liver, 32, 33 skin, [34] [35] [36] cornea, 37 blood vessels 38 and synovium of joints. 39 Furthermore, tumors such as malignant melanoma, [40] [41] [42] [43] glioma 44 and hepatocellular carcinoma 45 are good targets of electroporation.
As far as we know, however, there has been no report of electroporation applied to heart in vivo. The major reasons may be the necessity of invasive treatment, such as thoracotomy to directly attach the electrodes to the heart, and the possibility of side effects, such as arrhythmia. Indeed, today's electroporation instruments cannot easily be applied to the heart because of their risk to the patients. Meanwhile, transthoracic direct current (DC) shock has been widely applied to the heart, safely and effectively, in clinical practice for antiarrhythmic purposes for more than 50 years. 46 If these instruments are applicable to electrical gene transduction, then genetic treatment of the heart may be performed safely, effectively and at a low cost. In this study, to investigate the efficacy of gene transduction into cardiac muscle, transthoracic DC shock was administered after an intravascular injection of pDNA via a coronary catheter in canines.
Results
Transthoracic direct current shock enhances genetic transfer in vivo into myocardium
We first attempted intracoronary delivery of naked pDNA as a means for in vivo gene transfer into myocardium. pGEG.GL3, at a dose of 15 000 mg/15 ml, was divided into two aliquots and subjected to two consecutive retrograde intravenous bolus infusions into the coronary sinus. The heart was excised 1.5 days after infusion. The left ventricle (LV) was sectioned into 22 blocks as shown in Figure 1a , and the luciferase expression in each block was assayed. Very low luciferase expression was observed in all the regions tested (data not shown). Next, to achieve more persistent contact of pDNA with the cardiac tissue under high pressure, retrograde intravenous infusion of pGEG.GL3, at a total of 7000 mg, was performed after occlusion of the Myocardial transfection by transthoracic direct current shock Y Iida et al coronary sinus with a balloon, whereas antegrade infusion into the left coronary artery was concomitantly performed (protocol A; Figure 1b and c). Again, the luciferase gene expression after 1.5 days was very low, even at the heart blocks corresponding to the LAD regions that are supplied by the left anterior descending coronary artery (LAD; Figure 2a ). Then, we tried concomitant transthoracic DC shock with infusions into the coronary vein and artery, assuming that pulsed electric fields may promote delivery of pDNA into cardiomyocytes. After balloon occlusion of the coronary sinus, 200-J pulses were applied twice simultaneously with retrograde and antegrade intracoronary administrations of pGEG.GL3 at a total dose of 7000 mg (protocol B). After 1.5 days, significant luciferase expression was seen in many blocks (Figure 2b ). To statistically analyze the data, we calculated the luciferase activities in six parts (proximal, middle and distal areas of LAD and right coronary artery (RCA) regions), based on the anatomical distribution of the coronary arteries in each dog.
The statistical data are shown in Figure 3a . The luciferase expression was markedly increased in the distal (32 00075200 pg/mg protein), middle ( Figure 2 Luciferase expression 1.5 days after plasmid infusion. Hearts were transfected with pGEG.GL3 by protocol A (left panels, a) or protocol B (right panels, b) as described in Materials and methods (n ¼ 3 for each group. Each panel represents data from a single dog.) One and a half days later, the hearts were excised and sectioned into 22 blocks (see Figure 1b) . Luciferase activity and protein content in the lysate of each block were measured. Numbers on the horizontal axes represent the LV blocks Nos (see Figure 1a) . Figure 1a) . Figure 3a ). As a control experiment for protocol B, pGEG.EGFP lacking the luciferase gene was infused at a total dose of 7000 mg and DC pulsation was applied. On day 1.5, luciferase expression was not significantly detected in any regions tested (data not shown).
Localization of gene expression
In the canine hearts subjected to protocol B, high expression of luciferase was observed in LAD regions ( Figure 3a) . In sharp contrast, the expression was generally low in the blocks corresponding to the regions that were supplied by the RCA (Figure 1a ). To statistically demonstrate the localization of the gene expression, the luciferase levels in the LAD and RCA regions were compared. It was clearly shown that the transduction rate was significantly higher in both distal (32 00075200 vs 13007540 pg/mg protein, P ¼ 0.005) and middle (29 00077000 vs 320072500 pg/mg protein, P ¼ 0.03) LAD regions ( Figure 3b ). The proximal LAD regions showed a tendency to express higher luciferase levels than the proximal RCA regions, although statistically significant difference was not demonstrated between these regions (30 000710 000 vs 320071000 pg/ mg protein, P ¼ 0.06; Figure 3b ).
To investigate where in the LAD regions the gene was introduced, the anterior wall was excised from the canines 1.5 days after being subjected to protocol B, and divided into the endocardial, middle and epicardial layers. The luciferase gene was strongly expressed predominantly in the epicardial layer (23 00078400 pg/ mg protein), but much less expressed in the middle (770072200 pg/mg protein) and endocardial (32007 570 pg/mg protein) layers (Figure 3c ).
To histologically identify the genetically modified regions, the heart was transfected with a b-galactosidase (b-gal)-containing plasmid construct, pGEG.b, by protocol B and subjected to X-gal (5-bromo-4-chloro-3-indolylb-D-galactoside) staining. As shown in Figure 4a , the expression of b-gal was detected mainly in the anterior septum, which was consistent with the results of the luciferase assay ( Figure 2b ). In another experiment in which pGEG.GL3 was transfected into a dog by protocol B, cross-sections of the heart were not significantly stained with X-gal ( 
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To investigate which cell type in the heart was transfected, pGEG.EGFP was transduced into the heart by protocol B, and cryosections of the heart were subjected to immunohistochemical staining with antienhanced green fluorescent protein (EGFP) antibody. Figure 4c shows a representative microscopic image. It was revealed that 20-25% of cardiomyocytes successfully expressed the transgene product. The electrotransfection with a control plasmid did not result in EGFP expression at a detectable level (Figure 4d) .
The expression level of Luc remained high on day 5 after transfection ( Figure 5c ), whereas on day 12, the Luc activity was very low, if any (data not shown). The findings suggest that the transgene expression induced by electrotransfection does not persist for more than 12 days.
Influence of vascular malformation on gene transfer
Persistent left superior vena cava (LSVC) was observed in one dog (Figure 5d ). When the coronary sinus was occluded with a balloon, and retrograde intravenous infusion of contrast medium was performed, the contrast medium was not pooled in the vein, and was washed out through the angiectopia. Gene transduction using protocol B was performed in this animal, and localization of the luciferase expression was investigated on day 5. Compared with the normal dog (Figure 5a ), the level of expression was similar in the apex of the heart, but very low in the basal regions (Figure 5b ), suggesting that anomaly of coronary vasculature affected the genetic transfection. Regarding localization, the expression was predominant in the anterior wall, as in the normal dogs.
Side effect of cardiac catheterization and gene delivery
Intraoperative balloon occlusion of the coronary sinus decreased blood pressure and elevated the ST segment in the electrocardiogram (a representative electrocardiogram is shown in Figure 6a ). These findings may have reflected the ischemic condition in the heart. When the coronary sinus was occluded for 40 s after retrograde intravenous infusion or for 150 s without intravenous infusion, a mild elevation of the ST segment was observed during the occlusion, but this electrocardiographic (ECG) change was rapidly recovered after balloon deflation.
Transient ventricular arrhythmia occurred immediately after DC shock in some animals treated with protocol B, but sinus rhythm was rapidly resumed after intravenous administration of 20 mg lidocaine, and no problematic complication occurred.
In an animal that received a retrograde intravenous infusion, occlusion was maintained for a longer period to assess possible side effects of the procedure. On electrocardiography, the degree of ST elevation was drastically increased after about 40 s of occlusion, with mild prolongation of the QRS interval. When occlusion was further continued, severe hypotension and ventricular fibrillation occurred. The balloon was deflated at this point, but the animal died despite an attempt of defibrillation by lidocaine administration and DC shock. In the dogs treated with concomitant retrograde intravenous and antegrade intracoronary delivery with transthoracic DC shock (protocol B), echocardiography was performed before and 5 days after the gene transduction to investigate changes in the cardiac function. The LV remained normokinetic before and after gene transduction, without any evidence of localized abnormal wall movement (Figure 6b) . No significant changes were observed in the ventricular wall thickness, chamber size or fractional shortening (FS), showing that the treatment did not reduce the contractility of the LV (Table 1) .
We also performed biochemical analyses of dog sera before and after transfection by protocols A and B. Although MB fraction of creatinine phosphokinase (CPK-MB) slightly elevated after the transfection, the level decreased to normal range by day 1.5 (Table 2) . Any significant change was not seen in cardiac troponin T (cTnT) and C-reactive protein (CRP) levels before, immediately after and 1.5 days after gene transfer ( Table 2 ). The histopathological examination of heart sections did not show any significant sign of inflammation or cell injury on days 1.5 ( Figure 4c ) and 5 (data not shown). Gross morphological observation of cardiac cross-sections also failed to reveal any evidence of inflammation 12 days after electrotransfection (data not shown).
Discussion
In this study, we succeeded in percutaneous transluminal gene transfer into myocardium. In 16 dogs, the coronary sinus was occluded with a balloon to transiently pool the plasmid in the coronary vessels. Ten of the dogs received transthoracic DC shock, aiming at electric gene delivery. Coronary gene administration with concomitant transthoracic DC shock allowed efficient gene transduction.
Percutaneous catheter-mediated intracoronary delivery appears to be the most clinically relevant method, because of the capabilities of obtaining gene transduction in a specific region by choosing a coronary artery or vein that perfuses the target region, and because transduction in the target region is relatively homogeneous, compared with the direct intracardiomuscular injection method. Because of these advantages, transluminal procedures may be very useful when transduction into a wide area is necessary, such as in gene therapy for cardiomyopathy and cardiac failure. 
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Some previous studies also reported in vivo genetic transduction into the heart of large animals. Boekstegers et al. 11 transduced an adenovirus vector carrying luciferase gene into the heart of German farm pig, by means of selective pressure-regulated retroinfusion through the coronary veins with coronary artery occlusion, resulting in luciferase expression in endocardium of LAD at approximately 74 000 relative luciferase units (RLU)/ mg protein/30 s. March et al. 47 injected an adenovirus vector directly into the intrapericardial space of the mongrel dogs, showing that Luc expression reached 50 000 and o1000 RLU/mg protein/10 s in LV epicardium and endocardium, respectively. von Harsdorf et al. 48 performed direct naked pDNA injection into the epicardium in mongrel dogs, and Luc expressed at approximately 2200 RLU/mg protein/20 s. Our electrotransfection method may be inferior to the adenovirusmediated transduction, but superior to naked pDNA injection, in terms of the Luc expression in myocardium of large animals In mice, a rapid tail vein injection of naked pDNA induces a tremendously high-level expression of exogenous genes in the liver, [49] [50] [51] [52] whereas the procedure also results in significant gene delivery into the heart, albeit at a considerably lower rate. 50, 52 The skeletal muscle is also effectively transfected by intraarterial injection of pDNA in non-human primate. 53 In the present study, we obtained only low-level transgene expression in cardiomyocytes after intracoronary infusion of pDNA without electric pulsation (Figure 2a and data not shown), although the experiments were performed at a condition that may be suitable for naked DNA infusion (the dose of pDNA was 350 mg/kg body weight, and assay was performed on day 1.5). This may have been related to species differences in sizes of the organ and vascular lumen, coronary vasculature, flow volume and velocity of the coronary circulation, as well as biochemical characteristics of cardiomyocytes. Alternatively, the failure of intravascular pDNA transfection into cardiac muscle may be ascribed to insufficient pressure owing to the devices that were employed in this large animal model.
It is interesting to note that DC shock generates exponentially decaying wave pulses rather than square wave pulses. The efficiencies of electric gene transfer are highly affected by the electric field strength and pulse shapes. It is generally believed that square wave pulses are superior to exponentially decaying pulses, because the pulse duration and amplitude can be controlled independently, 54 and electroporation devices are designed accordingly. Square wave pulses of low field strength have been popularly employed in electroporation in vivo, whereas exponentially decaying wave pulses For three dogs, hearts were transfected with pGEG.GL3 by the protocol B, and echocardiographic examination was performed before and 5 days after the gene transduction. previously reported that an exponentially decaying wave pulse was suitable for electrotransfection in vitro, as it provided both the initial high voltage required for poration and the following low voltage 'tail' for electophoretical transfer of DNA molecules into the cell. The present study suggests that in vivo electroporation may also be achieved using not only square wave pulses but also exponentially decaying pulses, whereas the feasibility of another waveform was also presented recently. 57 It is conceivable that, to increase the transduction efficiency, the operation procedure should be designed in such a manner that the coronary vessel be in contacted with a high density of plasmid for a long time during the DC shock. The DC shock-dependent transduction was more effective when both intravenous infusion and intraarterial infusion were used together (protocol B), compared with when either of the two routes was used alone (data not shown).
The susceptibility of the cardiac muscle to ischemia poses a major challenge. Actually, in the animal in which the coronary sinus was occluded with a balloon for a prolonged period following retrograde intravenous infusion, severe hypotension and ventricular fibrillation was fatal (see 'Results'). Electrocardiographic monitoring should therefore be performed to detect ischemic change and arrhythmia, which may be induced by coronary balloon occlusion during the transfection procedure.
A balloon with a smaller diameter was applied to one dog during protocol B. No significant ST change was observed on ECG, suggesting that ischemia did not occur owing to insufficient occlusion. Interestingly, the transfection rate was very low in the heart of this dog (data not shown), suggesting the necessity of occlusion of the coronary sinus. As for the practicality of the present system for gene therapy of cardiac diseases, ECG changes should be confirmed on a case-by-case basis to demonstrate sufficient occlusion of the coronary vein, in order that efficient gene transduction can be achieved in the patient (Figure 6a) .
Another dog subjected to protocol B had congenital anomaly in cardiovascular morphogenesis, that is, the persistent left superior vena cava, as demonstrated by cardioangiography (Figure 5b ). Owing to a failure of regression of left anterior and common cardinal veins as well as left sinus horn, LSVC starts at the junction of left subclavian vein and left internal jugular, passes lateral to aortic arch and finally receives great cardiac vein to drain into coronary sinus (Figure 5d ). When the coronary sinus was occluded with a balloon and plasmid solution was infused into the coronary veins, the plasmid solution was washed out through the LSVC rather than pooled in the coronary vein. As the results, gene transduction was very low, except for in the apical region (Figure 5b ). This finding suggests that variation of the coronary vasculature among individuals affects the success rate of transfection into cardiac muscular regions. Therefore, the coronary vasculature of each patient should be checked by angiography before gene therapy.
Finally, it should be emphasized that the procedure does not require any specific device other than regular instruments used in ordinary hospitals, nor does it require of the cardiologists to have additional skills. This method may be applicable to gene therapy not only as a local treatment such as promotion of neovascularization in ischemic heart diseases but also for cases with wide lesions requiring repeated therapy such as in cardiac failure.
Materials and methods

Animals
Eight-month-old female beagle dogs weighing 9.1-10.4 kg were purchased from Oriental BioService (Kyoto, Japan). They received humane care in accordance with the institutional guidelines of Kyoto Prefectural University of Medicine.
Plasmid vectors
The plasmid vectors have been described previously. Briefly, pGEG.GL3, 52 pGEG.b 58 and pGEG.EGFP 39 carry the GL3 firefly luciferase (derived from pGL3-Basic Vector; Promega, Madison, WI, USA), Escherichia coli b-gal and the EGFP genes, respectively, under the control of the CAG promoter, whereas both plasmids also contain Epstein-Barr virus (EBV) nuclear antigen 1 gene, EBV oriP sequence and the ampicillin-resistant gene. 17 The plasmids were purified using EndoFree plasmid purification system (Qiagen, Hilden, Germany).
Cardiac catheterization and gene delivery
The dogs were sedated with an intramuscular administration of 100 mg ketamine, 30 mg xylazine and 0.5 mg atropine, and ventilated mechanically. Anesthesia was maintained by intravenous administrations of 50 mg ketamine every 30 min.
A 5F catheter introducer sheath (Medikit, Tokyo, Japan) was placed in the right femoral artery, and a 7F sheath was placed in the right external jugular vein. After an intravenous injection of 5000 U heparin and 20 mg lidocaine, a 5.0 Â 40 mm fluid-filled balloon catheter (Cordis, Miami, FL, USA) and a 4F coronary catheter (Medikit) were placed under fluoroscopic guidance in the coronary venous sinus and the left coronary artery, respectively.
Plasmid vectors were delivered under the following conditions. Protocol A: pGEG.GL3 at a dose of 3500 mg was diluted in 10 ml of saline and infused as a 5-s bolus retrogradely into the coronary vein through the lumen of the 'over the wire' balloon catheter, whereas another pGEG.GL3 solution (1750 mg/5 ml saline) was infused simultaneously as a 5-s bolus into the left coronary artery. During and after these procedures, the coronary venous sinus was occluded for 40 s by balloon inflation. Immediately after the manipulation, pGEG.GL3 solution (1750 mg/5 ml saline) was infused as a 5-s bolus into the coronary artery with occlusion of coronary venous sinus for 150 s. Protocol B: As protocol A except transthoracic DC shock of 200 J was applied immediately after the infusions into the coronary artery and vein. A commonly available clinical use instrument was used for the DC shock (TEC 7621, Nihon Kohden, Tokyo, Japan). In some experiments, pGEG.b or pGEG.EGFP was infused instead of pGEG.GL3.
After the procedures, all catheters and introducer sheaths were removed, the vessels were ligated and the wound surgically closed (day 0).
Myocardial transfection by transthoracic direct current shock Y Iida et al
Luciferase assay
The dogs were killed and the heart was perfused with heparinized saline solution (1 U/ml) infused via the aortic root. The LV of the excised heart was sectioned into the 22 blocks as shown in Figure 1a . Because each dog shows slight anatomical variation in coronary circulation, location of LAD and RCA was precisely recorded for each dog, so that raw data for the 22 blocks were pooled to calculate luciferase activities in distal, middle and proximal areas in LAD and RCA regions in subsequent statistical analyses (see below). In an experiment, epicardial, middle and endocardial layers were separated from each block, whereas in other experiments, epicardial layer of each block was collected. These specimens were homogenized in 200 ml reporter lysis buffer (Promega) using a sonicator. The extract was centrifuged at 10 000 g for 5 min. Luciferase activity in the supernatant was measured using a Luciferase Assay Kit (Promega) as described previously. 52 Photoemission was measured during a 10-s period using a luminometer. Protein concentration in the supernatant was measured as described. 52 
Statistical analyses
For statistical comparisons between two groups (protocols A vs B, and LAD vs RCA regions), differences were analyzed by unpaired t-test. For statistical comparisons among three groups (epicardial, middle and endocardial layers), differences were tested by analysis of variance with Schffe's correction. A value of Po0.05 was considered to be statistically significant.
X-gal staining
The heart was excised and horizontally sectioned into 3-mm-thick slices (from apex to basis). The slices were washed in phosphate-buffered saline (PBS) and incubated in X-gal staining solution (0.05% (v/v) X-gal (Nacalai Tesque, Kyoto, Japan), 1 mM MgCl 2 , 150 mM NaCl, 3 mM K 4 [Fe(CN) 6 ], 3 mM K 3 [Fe(CN) 6 ], 60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 and 0.1% Triton X-100) for 4 h at 371C. The reaction was terminated by replacing the solution with 1 mM Na 2 -EDTA/PBS. 59 
Immunohistochemistry
After perfusion with saline, the heart was excised, fixed with 4% paraformaldehyde and dehydrated in sucrose solution. The specimens were embedded in OCT compound and immediately frozen at À801C. Serial sections 6 mm thick were sliced on a cryostat, and stained with anti-GFP immunoglobulin (Molecular Probes, Leiden, the Netherlands) followed by visualization with the ABC method (VECTASTAIN elite ABC kit; Vector Laboratories, Inc., Burlingame, CA, USA). Sections were stained with hematoxylin after the immunohistochemical staining.
Electrocardiographic and echocardiographic examinations
Echocardiograhic studies were performed under anesthesia with an intramuscular administration of 100 mg ketamine, 30 mg xylazine and 0.5 mg atropine. A two-dimensional parasternal short-axis view of the LV was obtained at the level of the papillary muscles using echocardiographic system equipped with a 2.5 MHz phased-array transducer (SONOLAYER SSH-160A; Toshiba, Tokyo, Japan). The LV end-diastolic dimension, LV end-systolic dimension, FS, ejection fraction, enddiastolic interventricular septum thickness and enddiastolic posterior LV wall thickness were measured.
Examination of biochemical parameters
Sera were obtained before, immediately after and 1.5 days after gene transfer. Biochemical parameters including the CPK-MB, cTnT and CRP were measured by ADVIA Centaur immunoassay analyzer (Bayer Medical, Tokyo, Japan), ECLusys 2010 immunoassay analyzer (Roche Diagnostics, Tokyo, Japan) and Clinical Analyzer 7700 multiple automatic analyzer (Hitachi High-Technologies, Tokyo, Japan), respectively.
